Talem Therapeutics has been actively involved in COVID-19 research since January 2020. Monoclonal antibodies were derived from several animal species, including transgenic Omnirats® animals, rabbits, llama, and human, to access a broad epitope coverage. We exploit multiple antibody formats, valency, and size to select antibodies against multiple/rare epitopes. In a multi-national effort, involving our scientists in North America and Europe, Talem has now developed a rich and diverse discovery portfolio of SARS-CoV-2 candidate antibodies yielding epitope and functional diversity.
Our unique advantage is is how we source the antibodies, using multiple species (human, llama, Omnirats®, or rabbits), formats (scFv from human, VHH from llama, or full-length IgG from rat or rabbit), using various antibody discovery methods in vivo and in vitro (B cell, hybridoma and phage display), thereby leveraging the unique strengths inherent to each platform and compensating for their blind spots, since no single platform is universally the best approach for a given target or purpose.
Format and Formulation:
Species:
Format:
Discovery:
Taken together, we used a rich diversity of methods and platforms to increase the chance of converging upon a collection of lead candidates which can be rapidly reformulated and reformatted. This allows for PolyTope™ therapies to be continuously improved in response to emerging disease variants, improving durability of the therapy and leading expanded use to related indications.
Please contact bd@talemtherapeutics.com, if you are interested in learning more about the PolyTope™ Advantage in diagnosis or therapy of COVID-19
© 2020 All Rights Reserved